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Forty-two patients with refractory, recurrent life-threat•
ening ventricular tac;hycardia and spontaneous ventric•
ular tachycardia (2:3 beats, heart rate> IOQ beats/min) 
on baseline 24 hour Holter recor"ing were treated with 
amiodarone. After 1 week of amiodarone therapy and 
during the follow-up period (22 ± 11 months, mean ± 
SD), patients had serial 24 hour Holter r~cordings (10.6 
± 3.8 per patient). Twenty-four hour, 48 hour or 72 
hour Holter monitoring was performed during the sec•
ond week of therapy. Ventricular tachycardia was sup•
pressed on all follow-up serial Holter recordings in 17 
patients (40%). Ventricular tachycardia was suppressed 
in 34 (81 %) of 42 patients with 24 hour Holter record•
ings, 21 (72%) of 29 patients with 48 hour recordings 
and 20 (69%) of 29 patients with 72 hour recordings 
during the second week of therapy. At follow-up 24 pa•
tients (57%) were free of clinical arrhythmic events (sus•
tained ventricular tachycardia or sudden death). 
Amiodarone is a benzofuran derivative structurally similar 
to thyroxine, which was originally introduced in 1967 as an 
antianginal agent (1). In 1969 it was recognized as having 
antiarrhythmic potential and has been classified as a type 
III antiarrhythmic agent on the basis of its ability to prolong 
the action potential of atrial and ventricular muscle without 
changing the membrane resting potential (2-4). Although 
it has been used very effectively in supraventricular tach•
ycardias, its overall clinical efficacy in ventricular tachyar•
rhythmias has ranged from 52 to 100% (5-21). 
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The sensitivity, specificity, positive and negative pre•
dictive values and predictive accuracy of ventricular 
tachycardia on 24, 48 and 72 hour Holter recordings 
during the second week of therapy for predicting sub•
sequent events were analyzed. The positive and negative 
predictive values were 100 and 71 % for 24 hour Holter 
recordings, 88 and 71 % for 48 hour recordings and 89 
and 75% for 72 hour recordings. Overall predictive ac•
curacy was 76,76 and 79%, respectively. Although spec•
ificity decreased slightly from 100% on 24 hour Holter 
recordings to 94% on 48 or 72 hour recordings, sensi•
tivity increased from 44% on 24 hour recordings to 62% 
on 72 hour recordings. It appears t~at Holter monitoring 
during the second week of amiodarone therapy can be 
used to help identify patients at low risk or continued 
high risk for clinical arrhythmic events. 
(J Am Coil CardioI1985;6:806-13) 
The management of patients with ventricular tachyar•
rhythmias with amiodarone is complicated by the well doc•
umented disparity between clinical and electrophysiologic 
efficacy (15-18,22-25). In contrast to the experience with 
conventional type I antiarrhythmic agents, the ability to 
induce ventricular tachycardia by programmed electrical 
stimulation in patients receiving amiodarone does not por•
tend a poor clinical outcome. It is in this light tbat we 
examined a different perspective: the role of Holter electro•
cardiographic monitoring in the management of these pa•
tients. Although our overall experience with Holter moni•
toring as a guide to therapy with most antiarrhythmic agents 
in patients with ventricular tachyarrhythmias has been dis•
appointing compared with therapy guided by programmed 
stimulation (26), Holter monitoring may be predictive fQr 
selected agents (27). The data presented in this report sug•
gest that Holter monitoring is useful in the therapeutic man•
agement of patients receiving amiodarone. 
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Methods 
Patient profile. Forty-two patients were treated with 
amiodarone for refractory, recurrent life-threatening ven•
tricular tachycardia not associated with acute myocardial 
infarction; their clinical characteristics are summarized in 
Table 1. All patients had at least one episode (2.7 ± 1.6, 
mean ± SD) of documented spontaneous sustained ven•
tricular tachycardia within 1 year of referral. The clinical 
presentations were sudden death (cardiac arrest wi~hi~ 1 
hour of symptoms requiring cardiopulmonary resuscitatIOn 
or cardioversion, or both, from ventricular tachycardia or 
fibrillation in the absence of acute myocardial infarction) in 
17, syncope (transient loss of consciousness during the ar•
rhythmia with spontaneous recovery) in 13 and presyncope 
(lightheadedness accompanying the arrhythmia) in 12 pa•
tients. After discontinuation of antiarrhythmic drugs (other 
than digoxin and beta-receptor blockers) for at least five 
half-lives, all patients had spontaneous non sustained ven•
tricular tachycardia (2'::3 beats, lasting <30 seconds, heart 
rate > 100 beats/min) documented on the first continuous 
24 hour electrocardiographic monitoring before amiodarone 
therapy was begun, 
Underlying cardiac disease was defined by cardiac cath•
eterization. echocardiography and radionuclide studies. 
Coronary artery disease (defined by 2'::70% coronary artery 
narrowing) was present in 31 patients (74%), nonischemic 
congestive (dilated) cardiomyopathy (defined by diffuse hy•
pokinesia with ejection fraction :s 40%) in 8 patients (19%), 
mitral valve prolapse in 1 patient (2%) and no structural 
Table 1. Clinical Characteristics of 42 Patients 
Patients (no,) 
Male 
Female 
Age (yr) 
Ejection fraction (%) 
Cardiac disease 
Coronary artery disease 
Coronary artery disease, myocardial 
infarction 
Coronary artery disease, aneurysm 
Congestive cardiomyopathy 
Mitral valve prolapse 
No structural heart disease 
Clinical presentation 
Sudden death 
Syncope 
Presyncope 
Previous drugs failed 
Amiodarone dose (mg/day) 
Loading 
Maintenance 
Follow-up (mo) 
42 
36 
6 
60 ± 13 
36 ± 17 
31 (74%)* 
28 
14 
8 (19%) 
1(2%) 
2 (5%) 
17 
13 
12 
4.6 ± 1.5 
1,186 ± 93 
443 ± 102 
22 ± 11 
*Numbers in parentheses represent percent of total number of patients. 
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cardiac disease in 2 patients (5%). The ejection fraction was 
36 ± 17% (range 12 to 81) calculated from left ventricu•
lography at cardiac catheterization in all but four patients 
who had radionuclide estimates of overall left ventricular 
function. Twenty-eight (90%) of 31 patients with coronary 
artery disease had had at least one previous myocardial 
infarction and 14 had left ventricular aneurysm. One patient 
with cardiomyopathy and sarcoidosis had a left ventricular 
aneurysm. There were 13 patients in whom an automatic 
internal cardioverter-defibrillator (Intec Systems, Inc.) had 
been placed either before or during institution of amiodarone 
therapy. 
Previous drug failures. Previous drug failure was de•
fined as: 1) symptomatic arrhythmic event (sudden death, 
syncope or presyncope) while receiving the drug at thera•
peutic levels, 2) continued ventricular tachycardia (2':: 3 beats, 
heart rate> 100 beats/min) on subsequent serial Holter mon•
itoring after 48 hours of receiving the drug at therapeutic 
levels, 3) induction of ventricular tachycardia by pro•
grammed electrical stimulation while receiving the drug, or 
4) intolerable side effects. Patients had failed to respond to 
4.6 ± 1.5 drugs (range 2 to 8), All but three patients had 
failed at least one previous experimental drug before the 
institution of amiodarone therapy. 
Amiodarone administration. The oral loading dose of 
amiodarone ranged from 1,000 to 1,600 mg/day (1,186 ± 
93) for 14 days and the maintenance dose ranged from 200 
to 800 mg/day (443 ± 102). Thirty-six patients had a load•
ing dose of 1,200 mg/day for 14 days, which is our current 
loading dose; 33 patients had a maintenance dose of 400 to 
600 mg/day. Amiodarone was the only antiarrhythmic drug 
used on a long-term basis; any concomitant antiarrhythmic 
agents other than digoxin or beta-receptor blockers were 
discontinued 2 to 5 days after amiodarone therapy was 
initiated. 
Baseline data. Each patient gave informed consent be•
fore starting amiodarone therapy. Baseline evaluation in•
cluded physical examination, 12 lead electrocardiogram, 24 
hour Holter monitoring, complete blood count, basic blood 
chemistry screen including liver function tests, thyroid func•
tion tests and ophthalmologic evaluation including slit-lamp 
examination. Patients taking an anticoagulant agent or dig•
oxin had coagulation profiles or digoxin levels obtained with 
appropriate dose adjustments. 
All patients had at least one 24 hour Holter (Avionics, 
model 445B) recording before hospital discharge, and all 
patients had at least three such recordings after 1 week of 
amiodarone therapy. Serial Holter recordings during the 
second week of therapy were performed between days 8 
and 13. Twenty-four hour Holter monitoring was performed 
using dual-channel recordings. The magnetic tapes were 
analyzed using a Del Mar Avionics model 660 Dynamic 
Electrocardio-Scanner. All tapes were reviewed by at least 
two of the investigators and ventricular tachycardia was 
808 VELTRI ET AL. 
HOLTER MONITORING PREDICTS AMIODARONE EFFICACY 
~efined as three or more repetitive ventricular beats at a rate 
greater than 100 beats/min. The incidence of ventricular 
couplets and frequency of premature ventricular complexes 
were also quantified, as were the me;m and peak ventricular 
tachycardia rates on each 24 hour recording. 
Follow-up. Patients were followed up in the outpatient 
clinic of the Sudden Death Prevention Program at 2, 3, 4, 
6, 9 and 12 months after hospital discharge and then every 
6 months thereafter. At each visit repeat baseline variables, 
24 hour Holter recordings and history of interim sympto•
matic events (sudden death, syncope, pre syncope or auto•
matic internal cardioverter -defibrillator discharge) or any 
adverse effects were recorded. In addition, an external ana•
lyzer (AID Check, Intec Systems) was used to determine 
the number of discharges delivered to patients with an au•
tomatic internal cardioverter -defibrillator. 
A,"iodarone efficacy. The clinical efficacy of amio•
darone was based on the absence of clinical arrhythmic 
events (sudden death, automatic internal cardioverter-defi•
brillator discharge or sustained ventricular tachycardia man•
ifesting as either presyncope or syncope). Amiodarone was 
considered effective if the patient remained free of clinical 
arrhythmic events through follow-up. In cases of automatic 
internal cardioverter-defibrillator discharge, only the first 
out-of-hospital discharge was considered a sudden death 
event for that patient, even though patients may have ex•
perienced more than one automatic cardioversion. 
Statistical analysis. The data are presented as mean val•
ues ± SD. The significance of differences between two 
groups was determined by the Student's t test for unpaired 
data or by the chi-square test where appropriate; a proba•
bility value of less than 0.05 was accepted as the limit of 
significance. Kaplan-Meier actuarial curves (28) for amio•
darone efficacy were constructed and differences were as•
sessed with the use of the generalized Wilcoxon test (29). 
The sensitivity, specificity, positive predictive value, neg•
ative predictive value and predictive accuracy were defined 
as follows: sensitivity = TPffP + FN, specificity = TNITN 
+ FP, positive predictive value = TP/TP + FP, negative 
predictive value = TN/TN + FN and predictive accuracy 
= TP + TN/total popUlation, where TP = true positive 
(patients with ventricular tachycardia on Holter monitor and 
subsequent clinical arrhythmic event), TN = true negative 
(patients without ventricular tachycardia on Holter monitor 
and no clinical arrhythmic event), FP = false positive (pa•
tients with ventricular tachycardia on Holter monitor but no 
clinical arrhythmic event) and FN = false negative (patients 
without ventricular tachycardia on Holter monitor but with 
subsequent clinical arrhythmic event). 
Results 
Clinical outcome. At 22 ± 11 months (range I to 
42) follow-up, 15 patients (36%) were dead. There were 12 
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cardiac deaths, 8 of which were sudden as previously de•
fined; other cardiac deaths occurred in 3 patients with re•
fractory congestive heart failure and 1 with cardiogenic shock 
after aneurysmectomy. There were three noncardiac deaths 
(due to lung carcinoma, intracerebral hemorrhage and ac•
cident). The ejection fraction in patients who died from a 
cardiac cause was significantly lower than in patients alive 
at follow-up (28 ± 9 versus 39 ± 18%, p < 0.05). 
Twenty jour patients (57%) were free of clinical ar•
rhythmic events through follow-up. The range of the follow•
up period was 3 to 42 months in patients free of events. In 
the 18 patients (43%) with arrhythmic events, there were 
15 episodes of presyncope or syncope associated with sus•
tained ventricular tachycardia and 17 sudden ~eath events 
(including automatic internal cardioverter-defibrillator dis•
charge in 8 patients). Of the 30 patients with a previous 
history of syncope or sudden death, 9 (30%) experienced 
sudden death (including 5 patients with automatic internal 
cardioverter-defibrillator discharge as a sudden death event) 
at 22.8 ± 11 months follow-up. Of the 17 patients with a 
previous sudden death event, 6 (35%) had a recurrent sudden 
death event (including 5 patients with automatic internal 
cardioverter-defibrillator discharge as a sudden death event) 
at 26 ± 8 months follow-up. 
Table 2 summarizes the characteristics of patients with 
and without arrhythmic events. Ejection fraction was sig•
nificantly higher in patients with events (41 ± 19 versus 
32 ± 14%, P < 0.05). There were no significant differences 
in age, number of previous drugs failed, number of previous 
arrhythmic events, loading and maintenance doses, follow•
up period or number of Holter recordings performed. 
Figure 1 depicts the actuarial analysis of the efficacy of 
Table 2. Comparison of Patients With and Without 
Arrhythmic Events 
Event No Event p Value 
Patients 18 (43%)* 24 (57%) 
Age (yr) 55 ± 16 62 ± 9 NS 
EF (%) 41 ± 19 32 ± 14 p < 0.05 
Previous drugs failed 4.8 ± 1.6 4.5 ± 1.5 NS 
Previous events 2.7 ± 1.9 2.7 ± 1.2 NS 
Amiodarone dose (mg/day) 
Loading 1,183 ± 56 1,189 ± 128 NS 
Maintenance 447 ± 93 433 ± 114 NS 
Follow-up (mo) 20 ± 12 24 ± II NS 
Holter recordings/pt 10.8 ± 4.2 10.4 ± 3.6 NS 
Serial Holter monitoringt 
VT 13 (72%) 12 (50%) NS 
Couplets 16 (89%) 17(71%) NS 
1,000 PVCs/24 h 9 (50%) 10 (42%) NS 
*Numbers in parentheses represent percent of total number of patients. 
tCumulative serial Holter recordings 1 week after initiation of amiodarone 
therapy. EF = ejection fraction; pt = patient; PVCs = premature ven•
tricular complexes; VT = ventricular tachycardia. 
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Figure 1. Actuarial analysis of efficacy of amiodarone in 42 pa•
tients treated with amiodarone. 
amiodarone therapy. Of the 18 patients with arrhythmic 
events, 4 (22%) had an event within 1 month of starting 
amiodarone therapy, 5 (28%) by 2 months, 8 (44%) by 4 
months, 10 (56%) by 6 months and 15 (83%) by 12 months. 
All 19 patients free of arrhythmic events through 18 months 
of therapy remained free of events through the remaining 
follow-up period (11 ± 7 months). 
Holter monitoring outcome. Serial 24 hour Holter 
monitor recordings, 10.6 ± 3.8 per patient (range 3 to 17), 
were performed on all patients after 1 week of amiodarone 
therapy. Table 2 summarizes the cumulative Holter findings 
in patients with and without arrhythmic events. Of the 42 
patients, 17 (40%) were free of ventricular tachycardia on 
follow-up monitoring. Frequent premature ventricular com•
plexes (> 1 ,000124 h) were found in 50% of patients with 
events versus 42% of those without events (p = NS). Ven•
tricular couplets and ventricular tachycardia were frequent 
in both groups, albeit more so in patients with events, but 
again the difference between groups did not reach statistical 
significance. 
Of the 18 patients with arrhythmic events during follow•
up, 13 (72%) had ventricular tachycardia on Holter record•
ing as compared with 12 (50%) of 24 patients without events. 
Thus, the sensitivity and specificity of ventricular tachy•
cardia on serial Holter recordings as a test for arrhythmic 
events were 72 and 50%, respectively. The positive pre•
dictive value of ventricular tachycardia on Holter monitoring 
for predicting events was only 52%; however, the negative 
predictive value was 71 %. 
To examine a clinically more useful time period for serial 
24 hour Holter recordings performed after 1 week of amio•
darone administration, we looked at the value of the Holter 
recording performed during the second week of amiodarone 
therapy. There were 42 patients with one 24 hour recording, 
29 patients with two 24 hour recordings and 29 patients 
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Table 3. Findings on 24, 48 and 72 Hour Holter Recordings 
During the Second Week of Therapy in Patients With and 
Without Arrhythmic Events 
809 
Event No Event p Value 
Patients 18 24 
Holter VT 
24 hour 8 (44%) 0 P < 0.01 
48 hour 7 (54%)* I (6%)t P < 0.02 
72 hour 8 (62%)* I (6%)t p<O'o! 
*Thirteen of 18 patients with arrhythmic events had a 48 or 72 hour 
Holter recording. tSixteen of 24 patients without arrhythmic events had a 
48 or 72 hour Holter recording. VT = ventricular tachycardia. 
with three 24 hour recordings during the second week (Ta•
bles 3 and 4). Of the 18 patients with clinical arrhythmic 
events during follow-up, 8 (44%) had ventricular tachycar•
dia on 24 hour Holter monitoring during the second week 
of therapy as compared with none of the 24 patients without 
an event (p < 0.01). Seven (54%) of 13 patients with ar•
rhythmic events compared with 1 (6%) of 16 patients with•
out arrhythmic events had ventricular tachycardia on a 48 
hour recording during the second week of therapy (p < 
0.02). Eight (62%) of 13 patients with arrhythmic events 
compared with 1 (6%) of 16 patients without arrhythmic 
events had ventricular tachycardia on a 72 hour Holter re•
cording during the second week of therapy (p < 0.01). 
Figure 2 depicts the actuarial analysis of amiodarone effi•
cacy in patients with and without ventricular tachycardia on 
24 hour Holter monitoring performed during the second 
week of therapy. 
The positive and negative predictive values as well as 
overall predictive accuracy of 24, 48 and 72 hour Holter 
recordings during the second week of therapy were similar 
(Table 4). Although specificity decreased slightly from 100% 
for 24 hour to 94% for 48 hour or 72 hour Holter recordings, 
sensitivity increased from 44% for 24 hour to 62% for 72 
hour Holter recordings. 
Table 5 summarizes findings in patients with ventricular 
tachycardia on any serial 24 hour Holter recording through 
follow-up comparing patients with and without clinical ar-
Table 4. Ventricular Tachycardia on Any of One, Two or 
Three Serial 24 Hour Holter Recordings During the Second 
Week of Amiodraone Therapy Compared With Total 
Cumulative Holter Recordings During Follow-up Period 
No. of Recordings 
One (42)* Two (29) Three (29) Total (42) 
Sensitivity (%) 44 54 62 72 
Specificity (%) 100 94 94 50 
Positive predictive value (%) 100 88 89 52 
Negative predictive value (%) 71 71 75 71 
Predictive accuracy (%) 76 76 79 60 
*Numbers in parentheses represent number of patients. 
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Figure 2. Actuarial analysis of efficacy of amiodarone therapy in 
34 patients without (straight line) and 8 patients with (dashed 
line) ventricular tachycardia (VT) on 24 hour Holter monitoring 
during the second week of therapy. The difference between curves 
is significant at p = 0.002. 
rhythmic events. Twenty-five patients (60%) had ventricular 
tachycardia on serial 24 hour Holter recordings. Thirteen 
(52%) of these patients had subsequent clinical arrhythmic 
events. There were no significant differences in age, ejection 
fraction, mean and peak ventricular tachycardia rates on 
baseline Holter recording or mean and peak ventricular 
tachycardia rates on follow-up recordings in patients with 
and without events. Of particular interest is that cycle length 
changes during ventricular tachycardia did not predict clin•
ical outcome. 
Side effects. Major systemic side effects (hepatic, thy•
roid, pulmonary, neurologic, cardiac conduction and co•
agulation) were noted in 22 patients (52%). Discontinuation 
Table s. Comparison of Patients With and Without 
Arrhythmic Events and Ventricular Tachycardia on 
Follow-up Holter Monitoring 
Event No Event p Value 
Patients (no.) 13 12 
Age (yr) 55 :±: 18 62 :±: 10 NS 
EF(%) 40 :±: 22 33 :±: 12 NS 
Baseline 
Mean VT rate/pt 145 :±: 31 135 ± 14 NS 
(per min) 
Peak VT rate/pt 162 ± 49 162 ± 36 NS 
(per min) 
Receiving amiodarone 
Mean VT rate/pt 128 ± 16 131 ± 17 NS 
(per min) 
Peak VT rate/pt 138 ± 16 138 ± 20 NS 
(per min) 
EF :: ejection fraction; pt = patient; VT = ventricular tachycardia. 
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of amiodarone administration was necessitated in only 1 
(5%) of these patients. Minor side effects were ocular (cor•
neal microdeposits), noted in all patients tested, and der•
matologic (blue skin discoloration and photosensitivity), noted 
in three patients. Because of the innocuous nature of these 
latter side effects, no patient required drug discontinuation. 
No patients died because of adverse effects . 
Discussion 
This study supports the use of early Holter ambulatory 
electrocardiographic monitoring for the long-term prognos•
tic assessment of patients with refractory, recurrent life•
threatening ventricular tachycardia treated with amiodarone. 
Our results indicate that serial Holter monitoring during the 
second week of amiodarone therapy is useful in predicting 
the long-term outcome of high risk patients with previously 
documented episodes of sustained ventricular tachycardia 
and spontaneous nonsustained ventricular tachycardia on 
pretreatment 24 hour Holter monitoring. 
Clinical efficacy. Fifty-seven percent of patients were 
free of clinical arrhythmic events at 22 ± 11 months of 
follow-up. This extent of efficacy is within the range of 
previously reported studies (9-21), although somewhat lower 
than most (9-11,13-15,17,18,20,21). The discrepancy in 
efficacy rates may be multifactorial: first, differences in 
patient populations exist; second, loading dose, maintenance 
dose and duration of therapy vary and third, different end 
points and definitions of effectiveness of therapy are used 
from study to study. 
Of note, our patients had failed treatment with numerous 
previous drugs (4.6 ± 1.5) and had experienced numerous 
(2.7 ± 1.6) episodes of sustained ventricular tachycardia 
within 1 year of referral; thus, the efficacy rate of 57% at 
approximately 2 years of follow-up suggests a fairly good 
response in this high risk patient group. 
OJ the 30 patients with previous syncope or a sudden 
death event, only 9 (30%) experienced a sudden death event 
at 22.8 ± 11 months of follow-up. This is lower than the 
43% annual incidence rate of sudden death in the patients 
studied by Podrid and Lown (13). It is notable, however, 
that in our study an automatic internal cardioverter-defi•
brillator discharge in five patients was regarded as sudden 
death even though the tachyarrhythmia may have presented 
clinically as presyncope or syncope rather than sudden death, 
and thus, a 30% incidence rate may be spuriously high. 
Of the 17 patients whose original presentation was sud•
den death, 6 (35%) had recurrent sudden death at 26 ± 8 
months of follow-up. This is less than the 50% likelihood 
of recurrence over a 2 year period reported by Liberthson 
et al. (31) and Cobb et al. (32) in sudden death survivors. 
Our results do not concur, however, with the findings of 
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Peter et al. (33), who reported a 12% observed recurrent 
sudden death incidence at a median of 24 months of follow•
up in 33 survivors of sudden death treated empirically with 
amiodarone, or Morady et al. (34) who reported a 9% re•
current sudden death rate at 18 months of follow-up in 23 
patients with out-of-hospital cardiac arrest treated empiri•
cally with amiodarone. The failure to show significant im•
provement in recurrence of sudden death events in our study 
may be due to the inclusion of automatic internal cardio•
verter-defibrillator discharge as a sudden death occurrence 
in our study group. 
Although we have reported automatic internal cardio•
verter-defibrillator discharges during supraventricular 
tachyarrhythmias (35), internal cardioverter-defibrillator 
discharges in the present study had a history of supraven•
tricular tachyarrhythmias, and the premonitory symptoms 
before automatic internal cardioverter-defibrillator dis•
charge were all similar to those of previous episodes of 
ventricular tachyarrhythmias. It should be noted that no 
patient in this study achieved an exercise heart rate that met 
the rate cutoff criteria for the defibrillator. Thus, we believe 
that automatic internal cardioverter-defibrillator discharge 
as an end point is justified. Also, although drug intervention 
studies should ideally be double-blinded, we believe that 
the concept of a concurrent control group in study groups 
with an attendant 1 year mortality rate of 36 to 43% (30-32) 
is not pragmatic or ethical. 
We observed that arrhythmic events occurred relatively 
early after the institution of amiodarone therapy. Of the 18 
patients with arrhythmic events, 22% had an event within 
1 month and 56% within 6 months of starting therapy. This 
is in agreement with the failure rate at 1 month reported by 
Fogoros et al. (19), excluding patients with drug failure 
secondary to side effects in their series. All patients free of 
arrhythmic events through 18 months of follow-up study 
remained event-free. 
We unexpectedly found patients with arrhythmic events 
to have a significantly better ejection fraction than patients 
without such events. The reasons for this are not clear. In 
agreement with the findings of Swerdlow et al. (36), overall 
left ventricular function (ejection fraction) in patients with 
subsequent cardiac death was significantly poorer than that 
of those alive at follow-up in our series, emphasizing the 
importance of left ventricular function in prognosis. On the 
other hand, it may be that amiodarone is more protective 
in patients with poor left ventricular function but does not 
prolong survival. 
Role of Holter monitoring (previous studies). 
Numerous studies have revealed the discrepancy between 
the clinical and electrophysiologic efficacy of amiodarone 
therapy (15-18,22-25). Whereas programmed stimulation•
guided therapy is predictive of long-term efficacy with con•
ventional type I antiarrhythmic agents (37,38), this may not 
be the case with amiodarone therapy, although this possi-
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bility is controversial (39-41). Also, although serum amio•
darone concentrations less than 1.0 /Lg/ml may signal ar•
rhythmia relapse, serum concentrations do not differentiate 
responders and nonresponders (18). 
Few studies have assessed the value of Holter monitoring 
in predicting the clinical outcome of a therapeutic interven•
tion in patients with malignant ventricular arrhythmias. Pla•
tia and Reid (26) recently reported the predictive accuracy 
of suppression of ventricular tachycardia on Holter moni•
toring by antiarrhythmic agents to be only 55% in a series 
of 44 patients. This was significantly lower than the pre•
dictive accuracy of 91 % assessed by programmed stimu•
lation-guided therapy; however, only 2 of 44 patients were 
treated with amiodarone. Chua et al. (42) reported similar 
findings, with a predictive accuracy of only 41 % in suppres•
sion of Lown grade 3 or higher ectopic activity on Holter 
monitoring in 89 patients; the predictive accuracy of pro•
grammed stimulation-guided therapy was 82%. These in•
vestigators did not report how many patients, if any, were 
treated with amiodarone. Herling et al. (43) assessed the 
value of 24 hour Holter monitoring in 23 patients with 
recurrent ventricular tachycardia and concluded that the re•
sponse of ventricular ectopic activity to antiarrhythmic drug 
or surgical therapy did not predict therapeutic success. None 
of the patients treated with drugs was receiving amiodarone. 
In contrast to the previously mentioned studies, two stud•
ies have revealed reliability of Holter monitoring in pre•
dicting clinical response. Vlay et al. (27) recently reported 
that early abolition of asymptomatic ventricular tachycardia 
on 24 hour Holter monitoring can be used to predict a good 
long-term clinical response. They reported on 44 survivors 
of ventricular tachycardia and ventricular fibrillation who 
were treated with selected antiarrhythmic agents (aprindine, 
tocainide or bretylium) and followed up for at least 1 year. 
The predictive accuracy of a 24 hour Holter recording at 1 
month of therapy was 73%. These results concur with earlier 
results reported by Graboys et al. (30). These latter inves•
tigators reported on 123 patients with malignant ventricular 
arrhythmias and concluded that suppression of advanced 
grades of ventricular arrhythmia (Lown grades 4B and 5) 
provides an effective therapeutic objective. None of these 
patients was treated with amiodarone·. 
Several recent reports have attempted to correlate the 
effects of amiodarone on spontaneous ventricular arrhythmia 
in predicting clinical efficacy in patients with malignant 
ventricular arrhythmias (44-47). Kennedy et al. (44) re•
ported that a low level of ectopic activity on Holter moni•
toring after 4.5 weeks of amiodarone therapy in 24 patients 
studied was a good predictor of efficacy at a mean follow•
up time of 8 months. DiCarlo et al. (45), in a large series 
of 104 patients, reported the presence of ventricular tachy•
cardia on predischarge Holter monitoring in conjunction 
with an ejection fraction less than 40% and previous history 
of syncope or cardiac arrest as significant predictors of sub-
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sequent sudden death or cardiac arrest at approximately an 
8 month mean follow-up time. Marchlinski et al. (46) re•
ported that the predictive value of a good Holter response 
at a mean 11 days of amiodarone therapy was 82% in 55 
patients followed up for a mean of 13 months. Other studies 
have revealed a limited value of Holter monitoring in pre•
dicting clinical outcome (47). 
Present study. In contrast to these aforementioned stud•
ies, we have reported on a group of patients with one com•
mon variable documented on baseline Holter monitoring, 
namely, non sustained ventricular tachycardia, and corre•
lated clinical outcome based on the i!1fluence of amiodarone 
on this variable within a specified:!arly period of therapy. 
Thus, our group is more homogeneous and specific corre•
lations are perhaps more defined. In addition, the mean 
follow-up period in our patient group is longer. 
In the present study serial 24 hour Holter monitoring 
during the second week of amiodarone therapy provided 
useful predictive information. The positive and negative 
predictive values of early 24 to n hour Holter recordings 
ranged from 88 to 100 and 71 to 75%, respectively; the 
predictive accuracy was 76 to 79%. This period of Holter 
monitoring coincides with the mean time (9.5 days) required 
to achieve suppression of spontaneous ventricular tachy•
cardia on continuous electrocardiographic monitoring re•
ported by others (14,48) using comparable initial amioda•
rone doses. Preliminary results in a larger series of patients 
suggest that the incidence of supi>ression of nonsustained 
ventricular tachycardia is inc ased on Holter monitoring 
during the third week of ther~," 
The extension of Holte; /P, 'Hm'ngfrom 24 to 72 hours 
in 29 patients during the <~'_Cl!(' \'\';,~k of therapy increased 
the sensitivity of the test f ':n ,P hi 62% (approaching 72% 
noted on 10.6 ± 3.8 cun! iL"iv'~ lolter recordings per pa•
tient) and decreased the SF <[y only slightly from 100 
to 94%. 
Our results using early i+l:t, r p,onitoring are comparable 
with the results of McGown: et <11. (40) using programmed 
stimulation in predicting l<JEg,terrn clinical outcome. These 
investigators reported an 0'11:1':11 predictive accuracy of elec~ 
trophysiologic testing of 67";' in 42 patients with recurrent 
ventricular tachycardia or ventricular fibrillation treated with 
amiodarone. Discriminant amdysis increased the predictive 
accuracy to 79% in their study Baseline and follow-up 
spontaneous complex ventricular ectopic activity were not 
reported in their series, however, so further comparison of 
results is limited. 
Of 153 patients recently referred to our institution for 
evaluation of sustained ventricular tachyarrhythmias, 62 did 
not have basal 24 hour Holter monitoring performed because 
of technical difficulties or incessant ventricular arrhythmias; 
however, approximately 60% of the remaining patients had 
nonsustained ventricular tachycardia on 24 hour Holter mon•
itoring performed without any antiarrhythmic agents (un-
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published observations). Weaver et al. (49) reported that 
approximately 60% of patients resuscitated from cardiac 
arrest manifested ventricular repetitive forms (couplets or 
triplets) on subsequent 24 hour Holter monitoring. There•
fore, we believe that this noninvasive means of assessment 
would be practical in a large proportion of patients with a 
history of sustained ventricular tachyarrhythmias. 
Clinical implications. The ability to predict the efficacy 
of amiodarone by early, noninvasive means is practical and 
cost effective. The use of Holter monitoring is accessible 
and widespread in communities as opposed to the limited 
availability of electrophysiologic laboratories. Also, there 
is less attendant risk and cost compared with programmed 
electrical stimulation. Patients considered at continued high 
risk on the basis of persistent ventricular tachycardia on 
Holter monitoring could be considered for alternative ther•
apy early in the course of treatment, thereby obviating the 
side effects of amiodarone frequently seen during long-term 
therapy. 
We must caution against extending our conclusions to 
patients without documented episodes of sustained ventric•
ular tachycardia or patients with a history of presyncope, 
syncope or sudden cardiac death who do not manifest spon•
taneous nonsustained ventricular tachycardia on baseline 
Holter monitoring. In such patients serial Holter monitoring 
during amiodarone therapy may be of limited value and, 
indeed, the optimal means of assessing the clinical efficacy 
of amiodarone are not known. 
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